Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype

Published:2015-08 Issue:8 Volume:26 Page:1685-1691
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gnant M.,Sestak I.,Filipits M.,Dowsett M.,Balic M.,Lopez-Knowles E.,Greil R.,Dubsky P.,Stoeger H.,Rudas M.,Jakesz R.,Ferree S.,Cowens J.W.,Nielsen T.,Schaper C.,Fesl C.,Cuzick J.

Funder

AstraZeneca

NanoString Technologies

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/8/1685/16699719/mdv215.pdf

Reference17 articles.

1. Fighting overtreatment in adjuvant breast cancer therapy;Gnant;Lancet,2009

2. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004

3. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study;Dowsett;J Clin Oncol,2010

4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group (EBCTCG);Lancet,2005

5. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial;Gianni;Lancet Oncol,2011

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy;International Journal of Molecular Sciences;2024-05-24

2. The future of clinical trials—goals, ideas, and discussion;memo - Magazine of European Medical Oncology;2024-04-18

3. Clinical evaluation of deep learning-based risk profiling in breast cancer histopathology and comparison to an established multigene assay;Breast Cancer Research and Treatment;2024-04-09

4. Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study;JCI Insight;2024-04-08

5. Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry;Archives of Gynecology and Obstetrics;2024-03-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3